Capital World Investors 13F: Cuts ALNY Stake by $1.6B
Capital World Investors trimmed its Alnylam Pharmaceuticals stake by 33.7%, now holding 10.8 million shares.
Reviewed by automated data checks against the source filing. How we make and check alerts
Capital World Investors sold 5,499,424 shares from its stake in Alnylam Pharmaceuticals, Inc. ($ALNY), a 33.74% decrease, according to a 13F filing with the SEC dated May 13, 2026. It reported 10,802,348 shares worth $3.22 billion at the end of the quarter.
Since the filing, $ALNY is up 2.4% after 1 week, down 3.0% after 1 month and down 20.5% to date (from the $291.48 close on May 13, 2026).
Find the original: Capital World Investors 13F filings on SEC EDGAR
ALNY
Alnylam Pharmaceuticals, Inc.
Key Points
- Capital World Investors cut its Alnylam Pharmaceuticals position by 33.7%, selling 5,499,424 shares and now holds 10,802,348 shares valued at $3.23 billion.
- Alnylam Pharmaceuticals, trading around $298.65, has a market cap of $38.9 billion and a forward P/E of 21.17.
- Insiders were active, with notable transactions by David Pyott and Benjamin Cravatt, and analysts maintaining a buy consensus with a mean target of $436.32.
Get $ALNY trade alerts by text
We text you when insiders, Congress or big funds trade $ALNY. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Alnylam Pharmaceuticals, Inc. alert may contain errors. Disclosures
Capital World Investors, a major institutional investor, trimmed its stake in Alnylam Pharmaceuticals, Inc. (NasdaqGS: ALNY) by 33.7% during the most recent reporting period. The fund sold 5,499,424 shares, reducing its holdings to 10,802,348 shares, valued at approximately $3.23 billion, according to its latest Form 13F filing with the SEC.
Capital World Investors vs. the S&P 500
Hypothetical returns from Capital World Investors's disclosed trades, not real profit or advice. How we model this.
What Changed in Capital World Investors' Alnylam Pharmaceuticals Position
Capital World Investors cut its position in Alnylam Pharmaceuticals significantly, reducing its holdings by 33.7% from 16,301,772 shares to 10,802,348 shares. This move decreased the value of its investment to about $3.23 billion.
Other Institutional Activity in Alnylam Pharmaceuticals
FMR LLC reduced its holdings in Alnylam Pharmaceuticals by 1,322,983 shares, ending with 14,579,166 shares valued at $4.82 billion. BlackRock, Inc. slightly increased its position, adding 44,034 shares for a total of 10,444,908 shares worth around $3.46 billion. Capital Research Global Investors expanded its stake by 2,691,473 shares, now holding 9,471,181 shares valued at $3.13 billion. Vanguard Portfolio Management LLC opened a new position with 6,491,280 shares valued at about $2.15 billion.
Alnylam Pharmaceuticals, Inc. Stock Up 24.4%
Shares of Alnylam Pharmaceuticals traded near $298.65 on Saturday. The company's market capitalization stands at $38.9 billion, with a P/E ratio of 73.03 and a forward P/E of 21.17. The stock's 52-week range is between $273.11 and $495.55, while its 50-day and 200-day moving averages are $296.63 and $370.21, respectively. Alnylam has a beta of 0.267, indicating low volatility compared to the broader market.
Recent Earnings
Alnylam Pharmaceuticals reported revenue of $4.29 billion, showing a growth rate of 96.4%. The company achieved a net margin of 12.6% and a return on equity of 90.4%. Alnylam's next earnings report is expected on July 30, 2026.
Earnings drift grade
Outlook vs expectations on the last report — not price action.
-
Forward outlook
2 target cuts vs 1 raises.
-
EPS & revenue
EPS beat estimates by 56.5%. Revenue beat estimates by 2.7%.
-
Profit surprise
EBITDA missed by 5 percent. Operating income beat by 55 percent.
-
Pre-earnings setup
Bar was high, analysts already very bullish.
-
Analyst signal
1 target raise, 2 target cuts.
-
Earnings quality
Gross margin down 6.1 points. Operating margin up 20.0 points. Negative free cash flow.
Earnings Call Summary
Alnylam delivered 1.17 billion dollars in total product revenue in the first quarter, marking its first quarter exceeding 1 billion dollars. The TTR franchise generated 910 million dollars, up 153 percent year over year, with U.S. revenue growing 230 percent driven by strong AMVUTTRA adoption for heart disease. Management highlighted over 90 percent patient adherence to vutrisiran and broader international success including new launches in Europe and Japan, though Germany pricing adjustments created a temporary headwind that they expect to reverse in coming quarters.
Guidance Management reaffirmed full year guidance of 4.4 to 4.7 billion dollars in TTR revenue, expecting significantly higher quarter-over-quarter growth for the rest of 2026. They also expect the rare disease portfolio to continue contributing steady growth alongside the TTR cardiomyopathy launch expansion in international markets.
Negative report. Results or guidance disappointed and expectations are likely to move lower.
Insider Buying and Selling at Alnylam Pharmaceuticals, Inc.
Insider activity at Alnylam Pharmaceuticals included several transactions on June 1, 2026. David Pyott bought and sold 3,830 shares, with the sale planned under a 10b5-1 plan. Benjamin Cravatt also purchased 4,393 shares, and Amy Schulman acquired 838 shares on May 20, 2026.
Analysts Set New Price Targets
On May 19, 2026, Citigroup initiated coverage of Alnylam Pharmaceuticals with a buy rating and a $380 price target. RBC Capital maintained its buy rating with a $445 target on May 1, 2026. Wells Fargo also maintained a hold rating with a $377 target. The consensus among analysts is a buy rating, with an average price target of $436.32 based on 25 opinions.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc. is a biotechnology company based in Cambridge, Massachusetts. It specializes in developing and commercializing RNA interference-based therapeutics. The company offers treatments for various conditions, including hereditary transthyretin-mediated amyloidosis and hypercholesterolemia. Alnylam is also advancing a pipeline of products in various stages of clinical trials and has collaborations with several major pharmaceutical companies.
Bottom Line
Capital World Investors' decision to reduce its stake in Alnylam Pharmaceuticals reflects a significant portfolio adjustment. Investors closely follow these filings as they provide insights into institutional sentiment. It's important to remember that 13F filings are backward-looking and may not represent the current position of the fund.
Related Filing Alerts
Source: Capital World Investors's 13F filing on $ALNY (May 13, 2026). 13F filings show holdings as of the end of the reporting quarter and may not reflect the fund's current position. Find the original filing: Capital World Investors 13F filings on SEC EDGAR. Written by software, not financial advice. How we make alerts